Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
Neurocrine Biosciences 4Q 2025 Earnings Call - CRENESSITY Launch and INGREZZA Momentum Set Stage for 2026 Growth
Neurocrine closed 2025 with clear commercial momentum, driven by INGREZZA durability and a surprisingly strong first full year for CRENESSITY. Total product sales topped $2.8 billion, up 22% year over...
- Total product sales exceeded $2.8 billion in 2025, up 22% year over year, driven by INGREZZA and the first full-year of CRENESSITY sales.
- INGREZZA delivered just over $2.5 billion in revenue for 2025, up 9% year over year, with management forecasting approximately $2.7 to $2.8 billion in 2026, about 10% growth.
- Management expects INGREZZA 2026 growth to be volume driven, with double-digit unit growth offset partially by price concessions tied to formulary access investments.
- +12 more takeaways
Tamboran Resources FY2026 Q2 Earnings Call - On Track for First Gas in Q3 2026 as SPCF Nears Completion
Tamboran says the pilot is moving from trial to delivery. Management highlights the completion of the largest stimulation program in the Beetaloo so far, the Sturt Plateau compression facility trackin...
- Todd Abbott appointed CEO in January 2026 following an external process, signalling a management reset heading into production.
- Tamboran completed the largest stimulation program to date in the Beetaloo on SS-6H: 58 stages across a 10,009 foot horizontal in the Mid-Velkerri B Shale, executed with H&P FlexRig 3 and Liberty Energy frac fleet.
- Initial flow back from SS-6H identified an impediment at approximately 8,600 feet, potentially blocking flow from the last ~14 percent of the lateral; the impact is under evaluation.
- +15 more takeaways
Viking Therapeutics Q4 and Full Year 2025 Earnings Call - VK2735 advances to Phase 3 in both injectable and oral forms, maintenance study readout due Q3 2026
Viking closed 2025 with a clear, aggressive playbook: push VK2735 across two formulations into registrational studies while financing the effort with roughly $706 million in cash. The company has alre...
- VK2735 is now a dual-path Phase 3 program: subcutaneous VANQUISH program (VANQUISH-1 and VANQUISH-2) is underway and the oral formulation is planned to enter Phase 3 in Q3 2026 after a positive end-of-Phase 2 interaction with the FDA.
- VANQUISH-1 enrollment completed ahead of schedule and exceeded the planned ~4,500 patient target within five months; VANQUISH-2 (target ~1,100 patients, obesity plus type 2 diabetes) is nearing completion.
- VANQUISH trial design: randomized, double-blind, placebo-controlled, once-weekly subcutaneous dosing for 78 weeks with dose arms of 7.5 mg, 12.5 mg, and 17.5 mg, primary endpoint percent change in body weight at 78 weeks, plus extension periods for continued access.
- +12 more takeaways
Cisco Q2 FY2026 Earnings Call - AI Infrastructure Demand Drives Record Revenue, Memory Price Headwind
Cisco posted a clean, unmistakable beat in Q2, delivering record revenue of $15.3 billion, double-digit top- and bottom-line growth, and a clear AI narrative driving the outperformance. Product revenu...
- Record Q2 revenue $15.3 billion, up 10% year-over-year, Non-GAAP EPS $1.04, up 11%
- Total product revenue $11.6 billion, up 14%; services revenue $3.7 billion, down 1%
- Product orders rose 18% year-over-year, and excluding hyperscalers orders were up 10%
- +14 more takeaways
Vanda Pharmaceuticals Q4 2025 Earnings Call - Regulatory wins and product momentum, offset by a one-time $114m tax valuation that blew out 2025 results
Vanda closed 2025 with clear commercial traction and a flurry of regulatory milestones, but the headline numbers are distorted by a large, non-cash tax valuation allowance that turned a modest 2024 lo...
- Total 2025 revenue $216.1 million, up 9% year over year, driven primarily by Fanapt growth.
- Fanapt full-year net product sales $117.3 million, up 24% versus 2024; 2025 TRX rose 28% and new-to-brand prescriptions increased 149% year over year.
- Q4 2025 Fanapt sales $33.2 million, up 25% year over year; Q4 TRX +36% and Q4 NBRX +108% versus prior year quarter.
- +15 more takeaways
Fastly Q4 2025 Earnings Call - Revenue Acceleration and Record Gross Margins Show Profitability Turnaround
Fastly closed 2025 with a clear inflection, reporting a record Q4 and its first profitable fiscal year. Revenue accelerated to $172.6 million in Q4, up 23% year over year, driving a record gross margi...
- Q4 revenue $172.6 million, +23% year-over-year, above the high end of guidance and the largest sequential dollar growth in company history.
- Full-year 2025 revenue $624 million, +15% year-over-year, beating the prior year guidance midpoint.
- Q4 gross margin hit a record 64%, up 650 basis points YoY, driven by volume flow-through and a stronger traffic mix.
- +17 more takeaways
Apollo Commercial Real Estate Finance (ARI) Q4 and Full Year 2025 Earnings Call - Loan Portfolio Sale to Athene, Retaining Four REO Assets to Maximize Exit Value
ARI confirmed the previously announced sale of its loan portfolio to Athene, while keeping four REO assets it will actively manage to improve cash flow and maximize exit value. Management provided ope...
- ARI confirmed sale of its loan portfolio to Athene, while retaining four REO assets to manage and monetize separately.
- Company will actively manage the retained REO with a focus on run rate improvement, cash flow, and maximizing exit value, not a hold-for-operating-strategy by default.
- The Brook, a newly built 591-unit Class A multifamily in Brooklyn, is about 56% leased on market-rate units, with retail 88% leased, and management expects stabilization later in 2026.
- +14 more takeaways
AMC Networks Q4 2025 Earnings Call - Streaming Now Largest Domestic Revenue Source, FCF Beat
AMC Networks used 2025 to push its transformation: streaming became the largest single source of domestic revenue as the company delivered $272 million of free cash flow, well above its prior outlook....
- Streaming is now the largest single source of domestic revenue for AMC Networks, marking a structural inflection in the business mix.
- AMC generated $272 million of free cash flow in 2025, beating its prior outlook, and forecasts at least $200 million of free cash flow for 2026.
- Consolidated revenue for 2025 was $2.3 billion and consolidated adjusted operating income was $412 million, an 18% margin.
- +16 more takeaways
Biotricity Q3 FY2026 Earnings Call - High‑Margin Recurring Revenue Puts Small Company on a Near‑Term Path to Profitability
Biotricity reported modest top‑line growth but meaningful margin progress in Q3 FY2026, as revenue rose 10.2% year over year to $4.0 million and gross profit expanded to $3.2 million (gross margin 81....
- Revenue increased 10.2% YoY to $4.0 million for Q3 FY2026 (period ended Dec 31, 2025).
- Gross profit rose 17.6% to $3.2 million, pushing gross margin to 81.5%, a 516 basis point improvement year over year.
- Technology fees made up 91.2% of the quarter’s revenue, underscoring reliance on recurring, subscription‑style revenue over one‑time sales.
- +12 more takeaways
Outset Medical Q4 2025 Earnings Call - Next-Gen Tablo Clears FDA Under 2025 Cybersecurity Rules, Launch Late Q2
Outset closed 2025 with steady top-line growth and a company in hard-handed repair mode. Revenue for the year was $119.5 million, up 5% year over year, while margins expanded sharply and cash burn nar...
- FDA cleared Outset’s next-generation Tablo, the first dialysis system cleared under the FDA’s 2025 cybersecurity requirements, bringing multilayer authentication, secure-by-design architecture, and round-the-clock monitoring.
- Company plans a commercial launch of next-gen Tablo toward the end of Q2 2026, new units will ship with the upgrades, and existing customers will have a full upgrade path.
- Management positions the cybersecurity clearance as a competitive advantage that should drive incremental interest across hospital sizes, but specific ASP changes are not yet disclosed.
- +12 more takeaways